Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647702 | 0.78 | MLYCD (0.50) | MLYCD | |
| SCHEMBL650015 | 0.71 | MLYCD (0.54) | MLYCD | |
| SCHEMBL1900136 | 0.71 | MLYCD (0.72) | MLYCD | |
| SCHEMBL647994 | 0.69 | MLYCD (1.00) | MLYCD | |
| SCHEMBL3589385 | 0.69 | MLYCD (0.48) | MLYCD | |
| SCHEMBL1898629 | 0.68 | MLYCD (1.00) | MLYCD | |
| SCHEMBL1897897 | 0.68 | MLYCD (0.65) | MLYCD | |
| SCHEMBL11628816 | 0.68 | NAMPT (0.67) | SMN1; SMN2SORT1GSK3BL3MBTL1NAMPT | |
| Hydrochloric Acid SCHEMBL11627973 | 0.67 | SORT1 (0.65) | SMN1; SMN2SORT1GSK3BL3MBTL1NAMPT | |
| SCHEMBL3614049 | 0.67 | NAMPT (0.56) | SMN1; SMN2HSD17B10SORT1GSK3BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411929-B1 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-11 | — | — | EP | claimed |
| US-7524969-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-28 | — | — | US | claimed |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ME3, ACACA | MLYCD 1/4885SMN1; SMN2 2783/4885HSD17B10 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.